A recent study on mice, baboons and few volunteering patients revealed that a non-steroidal anti-inflammatory drug (NSAID) called meloxicam increases significantly the number of hematopoietic stem cells entering the blood stream. The study can potentially help patients requiring a hematopoietic stem cell (HSC), most notably leukemia victims. The study was carried out by researchers, led by Louis Pelus, at Indiana University's School of Medicine    #stemcells #leukemia

A recent study on mice, baboons and few volunteering patients revealed that a non-steroidal anti-inflammatory drug (NSAID) called meloxicam increases significantly the number of hematopoietic stem cells entering the blood stream. The study can potentially help patients requiring a hematopoietic stem cell (HSC), most notably leukemia victims. The study was carried out by researchers, led by Louis Pelus, at Indiana University's School of Medicine #stemcells #leukemia

Stem Cells Freak: Researchers develop iPSCs model of familial Alzhei...

Stem Cells Freak: Researchers develop iPSCs model of familial Alzhei...

In a study published yesterday, a team of researhers from the Sanford-Burnham Medical Research Institute and Johns Hopkins University describe how they created a new model for studying the Arrhythmogenic right ventricular dysplasia (ARVD) heart disease, by using induced pluripotent stem cells (iPSCs). According to the researchers, their model surpasses the existing ones, being way more suitable for both studying the condition and investigating new drugs and therapies.

In a study published yesterday, a team of researhers from the Sanford-Burnham Medical Research Institute and Johns Hopkins University describe how they created a new model for studying the Arrhythmogenic right ventricular dysplasia (ARVD) heart disease, by using induced pluripotent stem cells (iPSCs). According to the researchers, their model surpasses the existing ones, being way more suitable for both studying the condition and investigating new drugs and therapies.

OncoMed Pharmaceuticals announced today, that it will soon start Phase 1 human clinical trials on the OMP-52M51 product they have been developing. OMP-52M51 is an artificial monoclonan antibody that targets cancer stem cells (CSCs).

OncoMed Pharmaceuticals announced today, that it will soon start Phase 1 human clinical trials on the OMP-52M51 product they have been developing. OMP-52M51 is an artificial monoclonan antibody that targets cancer stem cells (CSCs).

CIRM funds more than $66 Million in research including new genomics initiative | Stem Cells Freak

CIRM funds more than $66 Million in research including new genomics initiative | Stem Cells Freak

New theory on how stem cells choose to become liver or pancreatic cells

New theory on how stem cells choose to become liver or pancreatic cells

MYOCARDIAL INFARCTION ➡ Partial interruption blood supply to part of heart muscle, causing heart cells damaged or die. Most commonly due to occlusion (blockage) of coronary artery following rupture of vulnerable atherosclerotic plaque, (unstable collection cholesterol, fatty acids, wbc's in wall of artery. Resulting ischemia (restriction in blood supply) & ensuing oxygen shortage, left untreated sufficient time, cause damage or death (infarction) of heart muscle tissue (myocardium). 5.17.13

MYOCARDIAL INFARCTION ➡ Partial interruption blood supply to part of heart muscle, causing heart cells damaged or die. Most commonly due to occlusion (blockage) of coronary artery following rupture of vulnerable atherosclerotic plaque, (unstable collection cholesterol, fatty acids, wbc's in wall of artery. Resulting ischemia (restriction in blood supply) & ensuing oxygen shortage, left untreated sufficient time, cause damage or death (infarction) of heart muscle tissue (myocardium). 5.17.13

OMICS Group’s Cell Science & Stem Cell Research Congress to explore the decent developments #stemcells

OMICS Group’s Cell Science & Stem Cell Research Congress to explore the decent developments #stemcells

Bioheart announces with Global Stem Cells Group to provide Bioheart therapies and training

Bioheart announces with Global Stem Cells Group to provide Bioheart therapies and training

Researchers from the Hubrecht Institute, Netherlands just announced that they have succeeded in growing stem cells with ability to develop into two different types of cells that make up a healthy pancreas. #stemcells #pancreatic

Researchers from the Hubrecht Institute, Netherlands just announced that they have succeeded in growing stem cells with ability to develop into two different types of cells that make up a healthy pancreas. #stemcells #pancreatic

Pinterest
Search